Wrapmanager Inc. Sells 4,280 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Wrapmanager Inc. decreased its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 35.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,959 shares of the medical research company’s stock after selling 4,280 shares during the period. Wrapmanager Inc.’s holdings in NeoGenomics were worth $220,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of NEO. FineMark National Bank & Trust lifted its stake in NeoGenomics by 1.6% in the 4th quarter. FineMark National Bank & Trust now owns 29,308 shares of the medical research company’s stock worth $857,000 after purchasing an additional 450 shares in the last quarter. Global Retirement Partners LLC raised its position in shares of NeoGenomics by 27.1% during the 1st quarter. Global Retirement Partners LLC now owns 2,110 shares of the medical research company’s stock valued at $58,000 after buying an additional 450 shares in the last quarter. Thrivent Financial for Lutherans raised its position in shares of NeoGenomics by 0.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 83,135 shares of the medical research company’s stock valued at $2,432,000 after buying an additional 614 shares in the last quarter. Fifth Third Bancorp raised its position in shares of NeoGenomics by 5.1% during the 1st quarter. Fifth Third Bancorp now owns 14,127 shares of the medical research company’s stock valued at $390,000 after buying an additional 683 shares in the last quarter. Finally, Sowell Financial Services LLC raised its position in shares of NeoGenomics by 66.1% during the 4th quarter. Sowell Financial Services LLC now owns 1,742 shares of the medical research company’s stock valued at $51,000 after buying an additional 693 shares in the last quarter. 86.77% of the stock is owned by hedge funds and other institutional investors.

In other news, Director Steven C. Jones sold 297,300 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $28.77, for a total transaction of $8,553,321.00. Following the transaction, the director now directly owns 195,234 shares in the company, valued at $5,616,882.18. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Robert J. Shovlin sold 98,093 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $30.86, for a total transaction of $3,027,149.98. Following the transaction, the insider now owns 249,733 shares in the company, valued at $7,706,760.38. The disclosure for this sale can be found here. 6.50% of the stock is owned by corporate insiders.

Shares of NEO stock opened at $28.18 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.18 and a quick ratio of 2.88. The company has a market capitalization of $2.93 billion, a P/E ratio of 939.65 and a beta of 0.79. The company’s 50-day simple moving average is $27.58 and its two-hundred day simple moving average is $28.17. NeoGenomics, Inc. has a one year low of $18.52 and a one year high of $34.97.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, April 28th. The medical research company reported ($0.02) EPS for the quarter, missing the Zacks’ consensus estimate of $0.02 by ($0.04). The company had revenue of $106.03 million during the quarter, compared to the consensus estimate of $106.03 million. NeoGenomics had a return on equity of 2.94% and a net margin of 0.82%. NeoGenomics’s revenue was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.03) earnings per share. On average, research analysts expect that NeoGenomics, Inc. will post -0.12 EPS for the current fiscal year.

Several analysts have recently issued reports on NEO shares. BidaskClub upgraded shares of NeoGenomics from a “hold” rating to a “buy” rating in a research report on Thursday, March 26th. Raymond James upped their target price on shares of NeoGenomics from $28.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, March 2nd. Craig Hallum started coverage on shares of NeoGenomics in a research report on Monday, March 2nd. They set a “buy” rating and a $38.00 target price on the stock. Needham & Company LLC restated a “buy” rating and set a $33.00 target price on shares of NeoGenomics in a research report on Wednesday, April 29th. Finally, First Analysis raised shares of NeoGenomics from an “outperform” rating to a “strong-buy” rating and set a $35.00 price objective on the stock in a research report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. NeoGenomics currently has an average rating of “Buy” and a consensus target price of $29.67.

NeoGenomics Profile

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

See Also: Asset Allocation

Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.